Trial record 3 of 3 for:    far infrared radiation treatment AND sclerosis

Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2009 by GAAD Medical Research Institute Inc..
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
GAAD Medical Research Institute Inc.
ClinicalTrials.gov Identifier:
NCT00674934
First received: May 6, 2008
Last updated: January 2, 2009
Last verified: January 2009

May 6, 2008
January 2, 2009
May 2008
May 2010   (final data collection date for primary outcome measure)
Treatment of MS [ Time Frame: 2 years ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00674934 on ClinicalTrials.gov Archive Site
Rehabilitation of MS Patients [ Time Frame: 2 Years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Far Infrared Irradiation for Managing and Treating Multiple Sclerosis (MS)
Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for Multiple Sclerosis.

Multiple sclerosis (abbreviated MS) is an autoimmune condition in which the immune system attacks the central nervous system (CNS), leading to demyelination. This study will investigate the use of far infrared radiation for MS control, management and treatment.

MS a demyelinating disease, is any disease of the nervous system in which the myelin sheath of neurons is damaged. This impairs the conduction of signals in the affected nerves, causing impairment in sensation, movement, cognition, or other functions depending on which nerves are involved.

MS affects the areas of the brain and spinal cord known as the white matter. White matter cells carry signals between the grey matter areas, where the processing is done, and the rest of the body. More specifically, MS destroys oligodendrocytes which are the cells responsible for creating and maintaining a fatty layer, known as the myelin sheath, which helps the neurons carry electrical signals.

Observations from our research studies indicate that, far infrared rays provide energy to the body, improve the autonomic functions of the nervous system, restore the functions of the endocrine system, strengthen the immune system, improve blood circulation and increase the level of oxygen in the cells and promote the regeneration of muscle cells, nerves and brain cells.

It is hereby postulated that irradiation using far infrared, with wavelength between 5 to 20 microns, of the central nervous system, the endocrine system and the whole body could prevent, control, manage or possibly lead to complete rehabilitation of people who have MS.

Interventional
Phase 1
Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Sclerosis
Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
Other Name: Far Infrared Radiation
Experimental: 1
Radiation
Intervention: Radiation: Far Infrared Radiation (5μm to 20μm wavelength)
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
5
June 2010
May 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with MS

Exclusion Criteria:

  • None
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00674934
GAAD-MS-CTP1
Yes
Dr. Kwasi Donyina/Founder & President, GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
Not Provided
Principal Investigator: Ken Nedd, M.D. GAAD Medical Research Institute Inc.
GAAD Medical Research Institute Inc.
January 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP